363 related articles for article (PubMed ID: 35433771)
1. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.
Chung T; Park YN
Front Med (Lausanne); 2022; 9():857140. PubMed ID: 35433771
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
3. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
Choi JH; Thung SN
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672619
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
[TBL] [Abstract][Full Text] [Related]
6. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
Sasaki M; Sato Y; Nakanuma Y
Virchows Arch; 2024 Mar; ():. PubMed ID: 38532197
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
8. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
9. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.
Akita M; Sofue K; Fujikura K; Otani K; Itoh T; Ajiki T; Fukumoto T; Zen Y
HPB (Oxford); 2019 Feb; 21(2):226-234. PubMed ID: 30170977
[TBL] [Abstract][Full Text] [Related]
10. Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.
Akita M; Yanagimoto H; Tsugawa D; Zen Y; Fukumoto T
Surg Today; 2024 Apr; ():. PubMed ID: 38563999
[TBL] [Abstract][Full Text] [Related]
11. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
[TBL] [Abstract][Full Text] [Related]
12. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
13. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
16. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
J Hepatol; 2024 Mar; ():. PubMed ID: 38508240
[TBL] [Abstract][Full Text] [Related]
17. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
18. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract][Full Text] [Related]
19. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
20. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
